- Home
- RERE vs ORIC Comparison
RERE vs ORIC Comparison
Compare RERE & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | ORIC |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.3M | 783.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RERE | ORIC |
|---|---|---|
| Price | $5.37 | $8.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $2,759,212,837.00 | N/A |
| Revenue This Year | $30.65 | N/A |
| Revenue Next Year | $24.64 | N/A |
| P/E Ratio | $32.56 | ★ N/A |
| Revenue Growth | ★ 27.95 | N/A |
| 52 Week Low | $2.00 | $3.90 |
| 52 Week High | $5.70 | $14.93 |
Technical Indicators
Market Signals| Indicator | RERE | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 64.83 | 27.80 |
| Support Level | $5.14 | $7.98 |
| Resistance Level | $5.70 | $8.62 |
| Average True Range (ATR) | 0.22 | 0.59 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 38.74 | 6.52 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.